LSDIF (Lucy Scientific Discovery) Cash Flow from Financing: $6.64 Mil (TTM As of Dec. 2023)


What is Lucy Scientific Discovery Cash Flow from Financing?

Lucy Scientific Discovery LSDIF Cash Flow from Financing is $6.64 Mil as of Dec. 2023.

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Lucy Scientific Discovery paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.76 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Lucy Scientific Discovery earned $0.76 Mil on financial activities for the three months ended in Dec. 2023.


Lucy Scientific Discovery  (OTCPK:LSDIF) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Lucy Scientific Discovery's issuance of stock for the three months ended in Dec. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Lucy Scientific Discovery's repurchase of stock for the three months ended in Dec. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Lucy Scientific Discovery's net issuance of debt for the three months ended in Dec. 2023 was $0.76 Mil. Lucy Scientific Discovery received $0.76 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Lucy Scientific Discovery's net issuance of preferred for the three months ended in Dec. 2023 was $0.00 Mil. Lucy Scientific Discovery paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Lucy Scientific Discovery's cash flow for dividends for the three months ended in Dec. 2023 was $0.00 Mil. Lucy Scientific Discovery received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Lucy Scientific Discovery's other financing for the three months ended in Dec. 2023 was $0.00 Mil. Lucy Scientific Discovery received $0.00 Mil on other financial activities.


Lucy Scientific Discovery Cash Flow from Financing Related Terms


Lucy Scientific Discovery Cash Flow from Financing Historical Data

* Premium members only.

The historical data trend for Lucy Scientific Discovery's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lucy Scientific Discovery Cash Flow from Financing Chart

Lucy Scientific Discovery Annual Data
Trend Jun21 Jun22 Jun23
Cash Flow from Financing
1.70 2.25 6.19

Lucy Scientific Discovery Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.14 5.88 0.00 0.00 0.76

Lucy Scientific Discovery Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Lucy Scientific Discovery's Cash from Financing for the fiscal year that ended in Jun. 2023 is calculated as:

Lucy Scientific Discovery's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Financing of $6.64 Mil mean?
Lucy Scientific Discovery (LSDIF) has a Cash Flow from Financing of $6.64 Mil as of Dec. 2023. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Lucy Scientific Discovery and its competitors.
Is Lucy Scientific Discovery's Cash Flow from Financing too high?
Lucy Scientific Discovery's current Cash Flow from Financing is $6.64 Mil.
How does Lucy Scientific Discovery's Cash Flow from Financing compare to INQD and ZTS?
Lucy Scientific Discovery's Cash Flow from Financing of $6.64 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Drug Manufacturers company?
A good Cash Flow from Financing depends on the Drug Manufacturers industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Lucy Scientific Discovery and its competitors. Lucy Scientific Discovery's current Cash Flow from Financing is $6.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucy Scientific Discovery stock overvalued right now?
Lucy Scientific Discovery (LSDIF) has a current Cash Flow from Financing of $6.64 Mil. The current Cash Flow from Financing is $6.64 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Lucy Scientific Discovery (LSDIF), the current Cash Flow from Financing is $6.64 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lucy Scientific Discovery Business Description

Address 301-1321 Blanshard Street, Victoria, BC, CAN, V8W 0B6
Lucy Scientific Discovery Inc is an early-stage psychotropics contract manufacturing company focused on becoming the contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. Its drug products are designed to treat a range of mental health and cognitive conditions.